Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05492500




Registration number
NCT05492500
Ethics application status
Date submitted
25/07/2022
Date registered
8/08/2022
Date last updated
17/05/2024

Titles & IDs
Public title
A Study of Ponsegromab in People With Heart Failure
Scientific title
A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE
Secondary ID [1] 0 0
2022-001809-50
Secondary ID [2] 0 0
C3651011
Universal Trial Number (UTN)
Trial acronym
GARDEN TIMI 74
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Heart Failure 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Coronary heart disease
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Main cohort: Ponsegromab low dose
Treatment: Drugs - Main cohort: Ponsegromab medium dose
Treatment: Drugs - Main cohort: ponsegromab high dose
Other interventions - Main cohort: Matched placebo
Treatment: Drugs - Open-label, PK Cohort: ponsegromab low dose
Treatment: Drugs - Open-label, PK Cohort: ponsegromab medium dose
Treatment: Drugs - Open-label, PK Cohort: ponsegromab high dose

Experimental: Main cohort: ponsegromab low dose - Participants will receive a low dose Q4W SC

Experimental: Main cohort: ponsegromab medium dose - Participants will receive a medium dose Q4W SC

Experimental: Main cohort: ponsegromab high dose - Participants will receive a high dose Q4W SC

Placebo Comparator: Main cohort: placebo - matched placebo

Experimental: Open-label, PK Cohort: ponsegromab low dose - Participants will receive a low dose Q4W SC

Experimental: Open-label, PK Cohort: ponsegromab medium dose - Participants will receive a medium dose Q4W SC

Experimental: Open-label, PK Cohort: ponsegromab high dose - Participants will receive a high dose Q4W SC


Treatment: Drugs: Main cohort: Ponsegromab low dose
Ponsegromab low dose subcutaneous injection

Treatment: Drugs: Main cohort: Ponsegromab medium dose
Ponsegromab medium dose subcutaneous injection

Treatment: Drugs: Main cohort: ponsegromab high dose
Ponsegromab high dose subcutaneous injection

Other interventions: Main cohort: Matched placebo
Matched placebo subcutaneous injection

Treatment: Drugs: Open-label, PK Cohort: ponsegromab low dose
ponsegromab low dose subcutaneous injection

Treatment: Drugs: Open-label, PK Cohort: ponsegromab medium dose
Ponsegromab medium dose subcutaneous injection

Treatment: Drugs: Open-label, PK Cohort: ponsegromab high dose
Ponsegromab high dose subcutaneous injection
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Main cohort: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Clinical Summary Score
Timepoint [1] 0 0
baseline, 22 weeks
Secondary outcome [1] 0 0
Main cohort: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Overall Summary Score
Timepoint [1] 0 0
baseline, 22 weeks
Secondary outcome [2] 0 0
Main cohort: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 Total Symptom Score
Timepoint [2] 0 0
baseline, 22 weeks
Secondary outcome [3] 0 0
Main cohort: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23 physical limitations domain
Timepoint [3] 0 0
baseline, 22 weeks
Secondary outcome [4] 0 0
Main cohort: Responses as defined by a =5 point increase from baseline in Kansas City Cardiomyopathy Questionnaire 23 Clinical Summary Score
Timepoint [4] 0 0
baseline, 22 weeks
Secondary outcome [5] 0 0
Main cohort: Responses as defined by a =5 point increase from baseline in Overall Summary Score
Timepoint [5] 0 0
baseline, 22 weeks
Secondary outcome [6] 0 0
Main cohort: Responses as defined by a =5 point increase from baseline in Total Symptom Score
Timepoint [6] 0 0
baseline, 22 weeks
Secondary outcome [7] 0 0
Main cohort: Responses as defined by a =5 point increase from baseline in physical limitation
Timepoint [7] 0 0
baseline, 22 weeks
Secondary outcome [8] 0 0
Main cohort: Change from baseline in 6-Minute Walk Distance
Timepoint [8] 0 0
baseline, 22 weeks
Secondary outcome [9] 0 0
Main cohort: Change from baseline in PROMIS-Fatigue 7a which will be completed by study participants on an electronic device, so as to compare the effect of ponsegromab versus placebo on fatigue as reported by participants with HF
Timepoint [9] 0 0
baseline, 22 weeks
Secondary outcome [10] 0 0
Main cohort: Incidence of treatment-emergent adverse events
Timepoint [10] 0 0
32 weeks
Secondary outcome [11] 0 0
Main cohort: Incidence of treatment-emergent serious adverse events
Timepoint [11] 0 0
32 weeks
Secondary outcome [12] 0 0
Main cohort: Incidence of abnormal laboratory results
Timepoint [12] 0 0
32 weeks
Secondary outcome [13] 0 0
Main cohort: Incidence of abnormal vital signs
Timepoint [13] 0 0
32 weeks
Secondary outcome [14] 0 0
Open-Label, PK Cohort: Incidence of treatment-emergent adverse events
Timepoint [14] 0 0
22 weeks
Secondary outcome [15] 0 0
Open-Label, PK Cohort: Incidence of treatment-emergent serious adverse events
Timepoint [15] 0 0
22 weeks
Secondary outcome [16] 0 0
Open-Label, PK Cohort: Incidence of abnormal laboratory results
Timepoint [16] 0 0
22 weeks
Secondary outcome [17] 0 0
Open-Label, PK Cohort: Incidence of abnormal vital signs
Timepoint [17] 0 0
22 weeks

Eligibility
Key inclusion criteria
- Male and female participants aged 18 years or older

-. Clinical evidence of HF with each of the following criteria:

1. LVEF <50% on most recent measurement, within 12 months of screening. Note: An
assessment of LVEF in the prior 12 months is not required in situations where
LVEF has been persistently <50% on prior assessments obtained at least 3 months
apart (including the most recent measurement).

2. NYHA class II-IV at screening.

3. Main cohort only: NT-proBNP =400 pg/mL at screening.

- Serum GDF-15 concentration =2000 pg/mL at screening.

- Main cohort only: KCCQ-23 CSS <75 at screening.

- Main cohort only: Evidence of cachexia or fatigue or functional impairment, as
demonstrated by at least one of the following at screening:

1. Non-edematous unintentional weight loss =5% in the last 6 months or current BMI
<20 kg/m2, associated with subjective fatigue or anorexia; or

2. Fatigue at least 3 times per week AND at least moderately bothersome fatigue in
the past 2 weeks based on the KCCQ-23 administered at screening; or

3. A score of <60 on the Physical Limitations Domain of the KCCQ 23 administered at
screening.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Acute decompensated HF within 1 month prior to Screening Visit 1 or during the
screening period.

- Implantation of a cardiac resynchronization therapy device or valve repair or
replacement within 3 months prior to randomization or intent to do so during the
trial.

For the open-label, PK cohort only: implantation of a cardiac resynchronization therapy
device more than 1 month prior to randomization is permitted.

- History of heart transplantation, currently listed for heart transplant,
current/planned mechanical circulatory support, or current/planned use of intravenous
inotropes (eg, dobutamine, milrinone).

- Acute coronary syndrome within 1 month prior to randomization.

- Coronary revascularization (percutaneous coronary intervention or coronary artery
bypass grafting) within 3 months prior to randomization or intent to undergo coronary
revascularization during the trial.

For the open-label, PK cohort only: coronary revascularization more than 1 month prior to
randomization is permitted.

- Untreated indication for an implantable cardiac defibrillator or pacemaker to treat a
cardiac rhythm abnormality (ie, tachyarrhythmia or bradyarrhythmia).

- Previous administration with an investigational product (drug or vaccine) within 30
days (or as determined by the local requirement) or 5 half lives (whichever is longer)
preceding the first dose of study intervention used in this study. Treatment with an
investigational biologic agent within 6 months or 5 half-lives (whichever is longer)
of Day 1.

- Previous exposure to ponsegromab in a prior clinical study.

- Renal disease requiring ongoing dialysis.

- Cirrhosis with evidence of portal hypertension not due to HF, or the following LFT
abnormalities at the time of screening, confirmed by a repeat test if deemed
necessary: AST or ALT level = 3 x ULN, or total bilirubin level = 2 x ULN (unless
history of Gilbert's syndrome).

Study design
Purpose of the study
Supportive Care
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
7/06/2025
Actual
Sample size
Target
416
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
Core Research Group - Brisbane
Recruitment hospital [3] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [4] 0 0
Gold Coast University Hospital - Southport
Recruitment hospital [5] 0 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment hospital [6] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
4064 - Brisbane
Recruitment postcode(s) [3] 0 0
4032 - Chermside
Recruitment postcode(s) [4] 0 0
4215 - Southport
Recruitment postcode(s) [5] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [6] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
Canada
State/province [16] 0 0
British Columbia
Country [17] 0 0
Canada
State/province [17] 0 0
Nova Scotia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
China
State/province [20] 0 0
Beijing
Country [21] 0 0
China
State/province [21] 0 0
Guangdong
Country [22] 0 0
China
State/province [22] 0 0
Hunan
Country [23] 0 0
China
State/province [23] 0 0
Jilin
Country [24] 0 0
China
State/province [24] 0 0
Shaanxi
Country [25] 0 0
China
State/province [25] 0 0
Shandong
Country [26] 0 0
China
State/province [26] 0 0
Shanghai
Country [27] 0 0
China
State/province [27] 0 0
Shanxi
Country [28] 0 0
China
State/province [28] 0 0
Tianjin
Country [29] 0 0
Czechia
State/province [29] 0 0
Jihomoravský KRAJ
Country [30] 0 0
Czechia
State/province [30] 0 0
Náchod
Country [31] 0 0
Czechia
State/province [31] 0 0
Praha 4
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha 10
Country [33] 0 0
Czechia
State/province [33] 0 0
Praha 2
Country [34] 0 0
Czechia
State/province [34] 0 0
Praha 6
Country [35] 0 0
Germany
State/province [35] 0 0
Hessen
Country [36] 0 0
Germany
State/province [36] 0 0
Niedersachsen
Country [37] 0 0
Germany
State/province [37] 0 0
Nordrhein-westfalen
Country [38] 0 0
Germany
State/province [38] 0 0
Sachsen
Country [39] 0 0
Germany
State/province [39] 0 0
Thuringia
Country [40] 0 0
Germany
State/province [40] 0 0
Thüringen
Country [41] 0 0
Hungary
State/province [41] 0 0
Baranya
Country [42] 0 0
Hungary
State/province [42] 0 0
Bács-kiskun
Country [43] 0 0
Hungary
State/province [43] 0 0
Békés
Country [44] 0 0
Hungary
State/province [44] 0 0
Gyor-moson-sopron
Country [45] 0 0
Hungary
State/province [45] 0 0
Nyíregyháza
Country [46] 0 0
Hungary
State/province [46] 0 0
Somogy
Country [47] 0 0
Hungary
State/province [47] 0 0
Budapest
Country [48] 0 0
Hungary
State/province [48] 0 0
Nagykanizsa
Country [49] 0 0
Japan
State/province [49] 0 0
Hyogo
Country [50] 0 0
Japan
State/province [50] 0 0
Iwate
Country [51] 0 0
Japan
State/province [51] 0 0
Miyagi
Country [52] 0 0
Japan
State/province [52] 0 0
Osaka
Country [53] 0 0
Japan
State/province [53] 0 0
Saitama
Country [54] 0 0
Japan
State/province [54] 0 0
Tokyo
Country [55] 0 0
Japan
State/province [55] 0 0
Kumamoto
Country [56] 0 0
Poland
State/province [56] 0 0
Dolnoslaskie
Country [57] 0 0
Poland
State/province [57] 0 0
Mazowieckie
Country [58] 0 0
Poland
State/province [58] 0 0
Podlaskie
Country [59] 0 0
Poland
State/province [59] 0 0
Pomorskie
Country [60] 0 0
Poland
State/province [60] 0 0
Warminsko-mazurskie
Country [61] 0 0
Poland
State/province [61] 0 0
Wielkopolskie
Country [62] 0 0
Poland
State/province [62] 0 0
Lodz
Country [63] 0 0
Poland
State/province [63] 0 0
Tychy
Country [64] 0 0
Poland
State/province [64] 0 0
Warsaw
Country [65] 0 0
Poland
State/province [65] 0 0
Warszawa
Country [66] 0 0
Poland
State/province [66] 0 0
Slaskie
Country [67] 0 0
Spain
State/province [67] 0 0
A Coruña [LA Coruña]
Country [68] 0 0
Spain
State/province [68] 0 0
Barcelona [barcelona]
Country [69] 0 0
Spain
State/province [69] 0 0
Barcelona
Country [70] 0 0
Spain
State/province [70] 0 0
Catalunya [cataluña]
Country [71] 0 0
Spain
State/province [71] 0 0
Madrid, Comunidad DE
Country [72] 0 0
Spain
State/province [72] 0 0
Murcia, Región DE
Country [73] 0 0
Spain
State/province [73] 0 0
Valenciana, Comunitat
Country [74] 0 0
Spain
State/province [74] 0 0
Granada
Country [75] 0 0
Spain
State/province [75] 0 0
Madrid
Country [76] 0 0
Spain
State/province [76] 0 0
Málaga
Country [77] 0 0
Spain
State/province [77] 0 0
Oviedo
Country [78] 0 0
Spain
State/province [78] 0 0
Sevilla
Country [79] 0 0
Spain
State/province [79] 0 0
Valencia
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Buckinghamshire
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Dundee CITY
Country [82] 0 0
United Kingdom
State/province [82] 0 0
England AND Wales
Country [83] 0 0
United Kingdom
State/province [83] 0 0
London, CITY OF
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Scotland
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Barnet
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Cambridge
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Clydebank
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Lincoln
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Liverpool
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Sheffield
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Stockton-On-Tees

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pfizer
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Thrombolysis In Myocardial Infarction (TIMI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The primary purpose of this clinical trial is to compare the effects of study medicine
(Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but
does not contain the active medicine) to find out if the study medicine is better than the
placebo (an injection that looks like the study medicine but does not contain the active
medicine) for treatment of symptoms related to heart failure. Participants will not know
which treatment group they are assigned to. Most participants in this study will receive the
study medicine or placebo by shots under the skin every four weeks. People may be able to
participate in this study if they have heart failure. Participants will take part in this
study for about 9 months. During this time participants will visit the study clinic once a
month.

A separate PK cohort within this clinical trial will receive open-label study medicine
(Ponsegromab/PF-06946860) only. Participants in this open-label, PK cohort will not receive
placebo. These participants will receive the study medicine by shots under the skin every
four weeks. People may be able to participate in this study cohort if they also have heart
failure. Participants will take part in the open-label, PK cohort for about 7 months.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05492500
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Country 0 0
Phone 0 0
1-800-718-1021
Fax 0 0
Email 0 0
ClinicalTrials.gov_Inquiries@pfizer.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05492500